Abstract
Nathan R. McCann, Francis J. Castellino
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
A novel coronavirus from patients with pneumonia in China, 2019
10.1056/nejmoa2001017 · 2020
A novel coronavirus genome identified in a cluster of pneumonia cases—Wuhan, China 2019–2020
10.46234/ccdcw2020.017 · 2020
The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
10.1038/s41564-020-0695-z · 2020
Naming the coronavirus disease (COVID-19) and the virus that causes it
Kept as external metadata until matched
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
10.1126/science.abb2507 · 2020
Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein
10.1016/j.cell.2020.02.058 · 2020
Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM
10.1126/sciadv.abe5575 · 2021
Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion
10.1038/s41586-020-2772-0 · 2020
The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex
10.1128/jvi.77.16.8801-8811.2003 · 2003
A pneumonia outbreak associated with a new coronavirus of probable bat origin
10.1038/s41586-020-2012-7 · 2020
SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
10.1016/j.cell.2020.02.052 · 2020
Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
10.1038/s41564-020-0688-y · 2020
Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion
10.1073/pnas.1708727114 · 2017
Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells
10.1073/pnas.2002589117 · 2020
TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells
10.15252/embj.2021107821 · 2021
TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells
10.26508/lsa.202000786 · 2020
Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development
10.1038/s41392-021-00558-8 · 2021
Mechanisms of SARS-CoV-2 entry into cells
10.1038/s41580-021-00418-x · 2022
Site-specific glycan analysis of the SARS-CoV-2 spike
10.1126/science.abb9983 · 2020
Site specific N- and O-glycosylation mapping of the spike proteins of SARS-CoV-2 variants of concern
10.1038/s41598-023-33088-0 · 2023
Quantitative profiling of N-glycosylation of SARS-CoV-2 spike protein variants
10.1093/glycob/cwad007 · 2023
Role for N-glycans and calnexin-calreticulin chaperones in SARS-CoV-2 Spike maturation and viral infectivity
10.1126/sciadv.abq8678 · 2022
10.1101/2020.06.26.173765
10.1101/2020.06.26.173765 · 2020
A glycan gate controls opening of the SARS-CoV-2 spike protein
10.1038/s41557-021-00758-3 · 2021
SARS-CoV-2 spike opening dynamics and energetics reveal the individual roles of glycans and their collective impact
10.1038/s42003-022-04138-6 · 2022
Beyond shielding: the roles of glycans in the SARS-CoV-2 spike protein
10.1021/acscentsci.0c01056 · 2020
Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition
10.1038/s41598-020-71748-7 · 2020
Computational epitope map of SARS-CoV-2 spike protein
10.1371/journal.pcbi.1008790 · 2021
SARS-CoV-2 simulations go exascale to predict dramatic spike opening and cryptic pockets across the proteome
10.1038/s41557-021-00707-0 · 2021
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
10.1038/s41586-020-2180-5 · 2020
Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology
10.1016/j.cell.2020.09.037 · 2020
Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection
10.1126/scitranslmed.abi9915 · 2021
The antigenic anatomy of SARS-CoV-2 receptor binding domain
10.1016/j.cell.2021.02.032 · 2021
Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
10.1016/j.chom.2021.02.003 · 2021
The receptor binding domain of SARS-CoV-2 spike is the key target of neutralizing antibody in human polyclonal sera
10.1101/2020.08.21.261727 · 2020
Rapid generation of neutralizing antibody responses in COVID-19 patients
10.1016/j.xcrm.2020.100040 · 2020
Cell entry mechanisms of SARS-CoV-2
10.1073/pnas.2003138117 · 2020
Controlling the SARS-CoV-2 spike glycoprotein conformation
10.1038/s41594-020-0479-4 · 2020
Modulation of SARS-CoV-2 spike binding to ACE2 through conformational selection
10.1038/s41565-025-01908-1 · 2025
Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation
10.1038/s41594-020-0483-8 · 2020
Jalview Version 2—a multiple sequence alignment editor and analysis workbench
10.1093/bioinformatics/btp033 · doi-reference
BeStSel: a web server for accurate protein secondary structure prediction and fold recognition from the circular dichroism spectra
10.1093/nar/gky497 · doi-reference
Accurate secondary structure prediction and fold recognition for circular dichroism spectroscopy
10.1073/pnas.1500851112 · doi-reference
SEDNTERP: a calculation and database utility to aid interpretation of analytical ultracentrifugation and light scattering data
10.1007/s00249-023-01629-0 · doi-reference
Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and Lamm equation modeling
10.1016/s0006-3495(00)76713-0 · doi-reference
Structural basis of receptor recognition by SARS-CoV-2
10.1038/s41586-020-2179-y · doi-reference
Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
10.1126/science.abd0826 · doi-reference
Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4
10.1038/cr.2013.92 · doi-reference
Role of arginine in the stabilization of proteins against aggregation
10.1021/bi047528r · doi-reference
The effects of arginine on refolding of aggregated proteins: not facilitate refolding, but suppress aggregation
10.1016/s0006-291x(03)00578-3 · doi-reference
Method for increasing the yield of properly folded recombinant human gamma interferon from inclusion bodies
10.1016/s0168-1656(96)01636-7 · doi-reference
The function of SARS-CoV-2 spike protein is impaired by disulfide-bond disruption with mutation at cysteine-488 and by thiol-reactive N-acetyl-cysteine and glutathione
10.1016/j.bbrc.2022.01.106 · doi-reference
Disruption of disulfides within RBD of SARS-CoV-2 spike protein prevents fusion and represents a target for viral entry inhibition by registered drugs
10.1096/fj.202100560r · doi-reference
Impact of thiol-disulfide balance on the binding of Covid-19 spike protein with angiotensin-converting enzyme 2 receptor
10.1021/acsomega.0c02125 · doi-reference
Disulfide bonds play a critical role in the structure and function of the receptor-binding domain of the SARS-CoV-2 spike antigen
10.1016/j.jmb.2021.167357 · doi-reference
Clustal W and Clustal X version 2.0
10.1093/bioinformatics/btm404 · doi-reference
Expasy, the Swiss Bioinformatics Resource Portal, as designed by its users
10.1093/nar/gkab225 · doi-reference
Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike
10.1016/j.cell.2022.04.035 · doi-reference
Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
10.1016/s1473-3099(22)00816-7 · doi-reference
Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection
10.1016/s1473-3099(23)00289-x · doi-reference
Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants
10.1016/j.celrep.2023.112443 · doi-reference
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
10.1016/j.cell.2022.12.018 · doi-reference
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
10.1038/s41564-022-01143-7 · doi-reference
Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles
10.1073/pnas.2200592119 · doi-reference
SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies
10.1126/scitranslmed.abn8543 · doi-reference
Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2
10.1016/j.chom.2022.04.014 · doi-reference
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
10.1038/s41586-021-04385-3 · doi-reference
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
10.1038/s41586-021-04388-0 · doi-reference
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
10.1038/s41586-021-04389-z · doi-reference
Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance
10.1038/s41423-021-00772-y · doi-reference
Antibody-mediated neutralization of authentic SARS-CoV-2 B.1.617 variants harboring L452R and T478K/E484Q
10.3390/v13091693 · doi-reference
Biophysical fitness landscape of the SARS-CoV-2 Delta variant receptor binding domain
10.1016/j.jmb.2022.167622 · doi-reference
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
10.1038/s41586-021-03944-y · doi-reference
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
10.1038/s41586-021-03777-9 · doi-reference
SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
10.1016/s2666-5247(21)00068-9 · doi-reference
Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected
10.1016/j.jinf.2021.07.019 · doi-reference
Insights into SARS-CoV-2’s mutations for evading human antibodies: sacrifice and survival
10.1021/acs.jmedchem.1c00311 · doi-reference
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
10.1038/s41586-021-03398-2 · doi-reference
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
10.1038/s41591-021-01318-5 · doi-reference
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
10.1016/j.cell.2021.03.036 · doi-reference